Loading
Developed the CD19 CAR-T therapy that became the first approved gene-modified cell therapy for cancer.
Carl H. June is the Richard W. Vague Professor in Immunotherapy and Director of the Center for Cellular Immunotherapies at the Abramson Cancer Center, University of Pennsylvania. He is known for developing the CD19 CAR-T therapy that became the first approved gene-modified cell therapy for cancer, leading the CTL019 programme that included Emily Whitehead's treatment in 2012 and culminated in the approval of tisagenlecleucel in 2017. His selected papers report chimeric antigen receptor-modified T cells in chronic lymphoid leukaemia and CAR T cells producing sustained remissions in leukaemia. His centre developed the 4-1BB CAR design now used widely, and he continues to work on gene-modified T cells for leukaemia and lymphoma.
| Title | Journal | Year |
|---|---|---|
| Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia | New England Journal of Medicine | 2011 |
| Chimeric antigen receptor T cells for sustained remissions in leukemia | New England Journal of Medicine | 2014 |
| ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL | New England Journal of Medicine | 2018 |
ELIANA turned CAR-T from a single-centre experiment into a licensed product and created the regulatory and logistical template every later cell therapy has followed. For children with refractory leukaemia it offers a chance of durable remission without transplant. The trial also exposed the gaps: manufacturing failures, patients dying while waiting, and roughly half relapsing within a few years.
This paper is the proof-of-concept for a living drug: a single infusion of a patient's own engineered T cells could eradicate leukaemia that had survived chemotherapy, transplant and antibody therapy. It defined cytokine release syndrome and its antidote, tocilizumab, and revealed antigen-loss relapse. It led directly to the first approved gene-modified cell therapy three years later.
Shares Emily Whitehead, Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL, Tisagenlecleucel, Abramson Cancer Center, University of Pennsylvania.
Shares Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL, ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL, Children's Hospital of Philadelphia, Abramson Cancer Center, University of Pennsylvania.
Shares Emily Whitehead, Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL, ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL, Abramson Cancer Center, University of Pennsylvania.
Shares Emily Whitehead, ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL, Tisagenlecleucel, CD19.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
Shares CD19, Chronic lymphocytic leukaemia, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
Shares Abramson Cancer Center, University of Pennsylvania, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.